A Rifaximin polymorphic mixture of / form in a relative ratio of 85/153 and a process for its preparation. The polymorphic mixture of Rifaximin is for use as a medicament, in particular in the treatment of traveler's diarrhea and hepatic encephalopathy. A pharmaceutical composition comprises the polymorphic mixture of Rifaximin as active ingredient, in particular, a solid formulation, more in particular, a film coated tablet. A polymorphic form of crude wet rifaximin and of purified wet rifaximin their use are used as intermediates in a process for the preparation of Rifaximin polymorphic mixture of / form in a relative ratio of 85/153.

The present invention relates to a tablet composition for oral administration of abiraterone acetate, particularly to pharmaceutical granulates and tablets giving immediate release of abiratetone acetate in the stomach.

The invention provides a solid composition of the peripheral mu opioid antagonist axelopran and a combination dosage form of the mu opioid antagonist axelopran sulfate in an immediate release form and an opioid analgesic agent which may be in an extended release, sustained release, modified release, or controlled release form and methods of preparing such a combination dosage form.

The purpose of present invention to provide a method for the production of an easy-to-take solid preparation, which is mainly characterized in that a coating processing for the easy-to-take property is simply performed by using a gelling agent in a dry process, without going through a wet condition, the easy-to-take solid preparation and the like. The present invention relates to a dry-process method for the production of an easy-to-take solid preparation wherein a compression-molded core is coated with a coating agent comprising a gelling agent that will show slipperiness when it is brought into contact with water, comprising directly applying only powder of the coating agent to a mortar inner surface, the bottom end surface of an upper-pestle, and the top end surface of a lower-pestle, and subsequently loading and integrally compression-molding a core-molding material; a powder composition for coating the solid preparation, which comprises a water-soluble polymer to be used in the aforementioned production method, and the like.

The purpose of present invention to provide a method for the production of an easy-to-take solid preparation, which is mainly characterized in that an outer layer-forming processing to provide an easy-to-take property is simply performed in a dry process without going through a wet condition so as to make the formed outer layer thicker; the easy-to-take solid preparation and the like. The present invention relates to a dry-process method for the production of an easy-to-take solid preparation wherein an inner core tablet is coated with a compression-molded outer layer-forming agent comprising a gelling agent that will show slipperiness when it is brought into contact with water, comprising loading separately or simultaneously the inner core tablet and powder of the outer layer-forming agent to a mortar inner surface, the bottom end surface of an upper-pestle, and the top end surface of a lower-pestle, and subsequently compression-molding them; a powder composition for coating a solid preparation for use in the above method, which comprises the water-soluble polymer and water-soluble sugar or sugar alcohol.

The present invention relates to pharmaceutical compositions comprising Ibrutinib. More particularly, the present invention relates to a tablet composition comprising Ibrutinib and one or more pharmaceutically acceptable excipients and process for preparing such compositions.

Disclosed is a pharmaceutical formulation containing esomeprazole or a pharmaceutically acceptable salt thereof. The pharmaceutical formulation, based on considerably improved pH-dependent drug release characteristics, starts to release the esomeprazole or a pharmaceutically acceptable salt thereof at a target delay time after oral administration, continues the release for a predetermined time, and finishes the release after a predetermined time, thereby providing excellent patient convenience and excellent therapeutic effects, as compared to conventional other formulations.

A pharmaceutical composition for colon targeting, a method for treating a colon-related disease using the same and a preparation method thereof are disclosed. The pharmaceutical composition of the present disclosure comprises: a core matrix comprising a cross-linked hydrogel and an active ingredient, wherein the active ingredient is dispersed in the cross-linked hydrogel, and a content of the active ingredient is 65 wt % to 95 wt % based on a total weight of the core matrix.

A solid dosage product having a tailored dissolution profile comprises a carrier block defining a plurality of compartments where each respective compartment is configured to receive one or more active pharmaceutical ingredient and the carrier block being digestible within an animal such that each respective active pharmaceutical ingredient is controllably released; and one or more coating layers applied to the carrier block. A method for manufacturing a solid dosage product having a tailored dissolution comprises manufacturing a digestible carrier block where the carrier block defines a plurality of compartments with each respective compartment configured to receive an active pharmaceutical ingredient; filling a respective compartment with a respective active pharmaceutical ingredient; and coating the carrier block with one or more coating layers.

An orally dispersible compound, which contains at least one ester or a salt of n-butyric acid, includes a granular material including at least one ester or salt of n-butyric acid and having a first and a second coating, and at least one excipient which is capable of making the granular material orally dispersible. The first coating includes from 20.0% to 99.0% by weight with respect to the first coating of saturated fatty acids with a C.sub.14-C.sub.22 long chain, and the second coating includes at least one thickening agent, the first coating being between the granular material and the second coating.